Podcast
MSL Talk: Tom Caravela, Mitchell D’Rozario
Finding Success as a Rare Diseases MSL
Summary
In this episode, Giovanni Passiatore delves into the complexities of working in the rare diseases arena as an MSL. Giovanni shares his extensive background and provides insights into the unique challenges faced in this field, including strategies for effective territory coverage and engaging with key opinion leaders. He highlights the critical role of patient identification and the emerging importance of patient diagnosis liaisons. Giovanni offers essential advice for aspiring MSLs, emphasizing the significance of humility, relationship-building, and business acumen. The episode wraps up with a focus on the resilience required for success in the MSL role and appreciation for the audience's engagement.
My guest today is Giovanni Passiatore, Head of US MSLs at Chiesi Rare Disease and he shares insights on how to find success as a Rare Diseases MSL
Giovanni discusses…
👉 What the industry considers “Rare Diseases” as a category
👉 Challenges Rare Diseases Medical Affairs/MSL teams face
👉 How the medical affairs strategy differs for a Rare Diseases company
👉 How metrics and KPIs may differ for Rare Disease MSLs
👉 Recommendations for Rare Disease MSLs to find success and become high performers in their territory
👉 What he looks for when hiring Rare Diseases MSLs
rare diseases MSL, medical science liaison challenges, key opinion leaders engagement, patient diagnosis liaisons, rare disease territory coverage
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Mitchell D’Rozario
Article
Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
Press Release
OVN Staff
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
Press Release
OVN Staff
Introducing OncologyVoiceNetwork.com
Article
A. Haslam, M.S. Kim, V. Prasad
Updated estimates of eligibility for and response to genome-targeted oncology drugs among US cancer patients, 2006-2020
Podcast
MSL Talk: Tom Caravela, Sarah Snyder